Top-News

Citius Oncology Aktie News

Aktie
WKN:  A40K7E ISIN:  US17331Y1091 US-Symbol:  CTOR Branche:  Pharmazeutika Land:  USA
1,12 $
+0,01 $
+0,90%
0,9619 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
76,96 Mio. €
Streubesitz
10,41%
KGV
-6,15
Index-Zuordnung
-

Citius Oncology News

04.12.25 - PR Newswire
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim PR Newswire
01.12.25 - PR Newswire
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) PR Newswire
25.11.25 - PR Newswire
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting PR Newswire
21.11.25 - PR Newswire
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration PR Newswire
20.10.25 - PR Newswire
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch PR Newswire
17.10.25 - PR Newswire
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR Newswire
16.10.25 - PR Newswire
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ PR Newswire
08.10.25 - PR Newswire
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 PR Newswire
08.10.25 - PR Newswire
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 PR Newswire
07.10.25 - PR Newswire
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe PR Newswire
10.09.25 - PR Newswire
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
09.09.25 - PR Newswire
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
22.08.25 - PR Newswire
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch PR Newswire
12.08.25 - PR Newswire
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
06.08.25 - PR Newswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire
06.08.25 - PR Newswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire
17.07.25 - PR Newswire
Citius Oncology Announces Closing of $9.0 Million Public Offering
Citius Oncology Announces Closing of $9.0 Million Public Offering PR Newswire
16.07.25 - PR Newswire
Citius Oncology Announces Pricing of $9.0 Million Public Offering
Citius Oncology Announces Pricing of $9.0 Million Public Offering PR Newswire
15.07.25 - PR Newswire
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora PR Newswire
08.07.25 - PR Newswire
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »